KLKB1 gene editing therapy reduces kallikrein levels in hereditary angioedema

1. In this randomized controlled trial, gene-editing therapy targeting the kallikrein B1 gene (KLKB1) led to a significant reduction in plasma kallikrein levels among adults with hereditary angioedema (HA). 2. Trial participants also saw a reduction in angioedema attacks in the following 16 weeks and had no severe adverse events.  Evidence Rating Level: 1 (Excellent) […]

The post KLKB1 gene editing therapy reduces kallikrein levels in hereditary angioedema first appeared on 2 Minute Medicine.